Apixaban Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 2.5 mg, 5 mg
Reference Brands: Eliquis(US & EU)
Category:
Blood Disorder
Apixaban inhibits factor Xa, reducing thrombin generation and preventing blood clots. It effectively lowers the risk of stroke, deep vein thrombosis, and pulmonary embolism. Benefits include oral administration, predictable effects, no routine monitoring needed, rapid onset, and reduced bleeding risk, making it a preferred anticoagulant for various thromboembolic conditions.
Apixaban tablet is available in Tablet
and strengths such as 2.5 mg, 5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Apixaban tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Apixaban tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Apixaban is approved by regulatory authorities in both the EU and US for various indications, including stroke prevention in atrial fibrillation and treatment of DVT/PE. In the US, it is approved by the FDA, requiring a comprehensive dossier demonstrating safety, efficacy, and manufacturing quality. In the EU, approval is granted through the EMA’s centralized procedure, adhering to strict biosimilar and medicinal product standards. Accurate dossier preparation, including pharmacovigilance plans, stability data, and clinical trial evidence, is essential for market authorization. For expert guidance on regulatory strategy, dossier development, and market entry, visit PharmaTradz. Ensuring compliance facilitates smooth approval processes and successful commercialization worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing